Statement of EFSA on a study associating bisphenol A with medical disorders

Tabs

Article
doi
10.2903/j.efsa.2008.838
European Food Safety Authority
Acknowledgement

This statement was prepared by the EFSA Unit on food contact materials, enzymes,
flavourings and processing aids (CEF) and the Unit on Assessment Methodology (AMU).
EFSA wishes to thank the following members of the CEF Panel for their scientific advice
during the drafting of this statement: Jean-Claude Lhuguenot, Wim Mennes and Detlef
Woelfle.

Type
Statement of EFSA
Question Number
EFSA-Q-2008-702
Approved
22 Octobre 2008
Published
24 Octobre 2008
Affiliation
European Food Safety Authority (EFSA), Parma, Italy
Note
Article (28.19 KB)28.19 KB
Summary

The European Food Safety Authority (EFSA) received a request on 29 September 2008 from the European Commission requesting an assessment of the implications to the hazard and risk assessment of bisphenol A (BPA) of a study published in the Journal of the American Medical Association (JAMA) on 16 September (Lang et al., 2008), correlating urinary BPA concentrations to medical disorders in adults.

The former EFSA Panel on food additives, flavourings, processing aids and materials in contact with food (AFC) carried out a comprehensive risk assessment on bisphenol A (BPA) in 2006 and set a full Tolerable Daily Intake (TDI) of 0.05 mg/kg body weight (bw)/day.

EFSA concluded that this single study does not provide sufficient proof for a causal link between exposure to BPA and the health conditions mentioned in the study, i.e. heart disease, diabetes and elevated liver-enzyme activities. Therefore, EFSA considers that there is no need to revise the TDI as derived by the AFC Panel in 2006.

Keywords
Bisphenol A, CAS no. 80-05-7, cardiovascular disease, diabetes, liver-enzyme abnormalities